Core Viewpoint - Multiple securities firms, including Dongfang Securities, Zheshang Securities, and CITIC Securities, have issued positive ratings for Dazhenglin (603233.SH), highlighting its performance in 2024 and Q1 2025, business layout, and future prospects [1][2]. Group 1: Financial Performance - In 2024, Dazhenglin achieved a revenue of 26.497 billion yuan, representing a year-on-year growth of 8.01%, with a net profit attributable to shareholders of 915 million yuan [1]. - For Q1 2025, the company reported a revenue of 6.956 billion yuan, a year-on-year increase of 3.02%, and a net profit of 460 million yuan, reflecting a significant year-on-year growth of 15.45% and a remarkable quarter-on-quarter surge of 712.26% [1]. Group 2: Business Expansion and Network - As of March 2025, Dazhenglin operates a total of 16,622 stores, including 6,239 franchise stores and 10,383 direct-operated stores, covering 21 provinces across the country [2]. - The company plans to focus on optimizing its store network and accelerating franchise development in 2025, aiming to enhance market share and brand influence in underrepresented areas [2]. Group 3: Digital Transformation and New Retail - Dazhenglin is advancing its new retail channels and digital initiatives, with over 110 million private domain members and nearly 60 million active members as of the end of 2024 [3]. - The company has implemented an O2O delivery service with an 80.38% store coverage rate and is enhancing its online and offline integration through a "central warehouse + provincial warehouse + regional warehouse + store" model [3]. - The introduction of AI technology, such as "AI Xiaosan," aims to improve operational efficiency by providing accurate instant responses and intelligent analysis [3].

业绩摘要：2024 年实现营业收入264.97 亿元/+8.01%，归母净利9.15 亿元/-21.58%；其中24Q4 实现收入 67.66 亿元/-0.63%，归母净利0.57 亿元。 25Q1 实现收入69.56 亿元/+3.02%，归母净利4.60 亿元/+15.45%。 中西成药增长稳健，非药品类承压。分产品看，2024 年公司中西成药收入199.68 亿元/+12.82%，毛利 率 30.00%/-1.16pct，中西成药作为刚需品类保持稳健增长。中参药材收入 29.45 亿元/-0.99%，毛利率 42.32%/-0.56pct；非药品收入 29.48 亿元/-9.52%，毛利率 41.72%/-1.80pct。中参药材和非药品受消费力 下行影响较大，后续销售有望随宏观环境好转迎来改善。 优化门店布局进入加密期，持续加强精细化管理。24H1 公司完成上海和内蒙古覆盖后，基本完成跨省 扩张布局，自24H2 起正式进入加密期，聚焦提升已进入省份的市占率，加强精细化管理，盈利能力有 望优化。截至25Q1末，公司门店覆盖全国21 个省，门店数量达16,622 家。2024 年，公司净增门店 2,479 ...